Target discovery for T cell therapy: next steps to advance Immunotherapies

Journal for ImmunoTherapy of Cancer

Kai W Wucherpfennig^1,10  Paul F Robbins⁶  Carlos A Ramos⁵  Laszlo Radvanyi⁴  Yoav Peretz^1,11  Richard Morgan⁹  Achim A Jungbluth^1,12  Emma Hickman⁷  Stanley R Frankel⁸  Zelig Eshhar³  Joanna E Brewer²  Adrian Bot¹ 

[1] Translational Medicine, Kite Pharma Inc., 2225 Colorado Avenue, Santa Monica, 90404, CA, USA;Cellular Biology, Adaptimmune Ltd., Abingdon, UK;Immunology, The Weizmann Institute of Science, Rehovot, Israel;Lion Biotechnologies, Woodland Hills, CA, USA;Medicine, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA;DNA Sequencing and FACS Cores, Surgery Branch; Staff Scientist, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA;Target Validation, Immunocore, Abingdon, UK;Oncology Early Development, Therapeutic Area Head, Amgen, Thousand Oaks, CA, USA;Immunotherapy, Bluebird Bio, Boston, MA, USA;Cancer Immunology & AIDS, Dana-Farber Cancer Institute; Professor of Neurology at Harvard Medical School, Cambridge, MA, USA;Immunology, ImmuneCarta, Caprion, Montreal, Quebec, Canada;Immunohistochemistry, Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

关键词: Vaccines;    Antibodies;    Adoptive T cell therapy;    Targets;    Tumor infiltrating lymphocytes;    T cell receptors;    Chimeric antigen receptors;    Adoptive T cell therapy;    Immunotherapy;   

Others  :  1221147
DOI  :  10.1186/s40425-015-0061-5

 received in 2015-03-02, accepted in 2015-03-25,  发布年份 2015

【 摘 要 】

Investigators from academia and industry gathered on August 14, 2014, in Boston at the Inaugural ImVacS conference entitled “Target Discovery for T Cell Therapy: Next Step to Advance Immunotherapies”. Novel targets, discovery strategies and enabling technologies were presented and discussed.

【 授权许可】

   
2015 Bot et al.; licensee BioMed Central.